Phaseline

Companies › Vaderis Therapeutics

Vaderis Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Cardiovascular, Other; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Engasertib–Phase 3Hereditary Hemorrhagic Telangiectasia; Healthy ParticipantsJun 2028
VAD044–Phase 1Hereditary Hemorrhagic Telangiectasia (HHT)Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07800429EngasertibPhase 1Healthy ParticipantsOtherOct 2026
NCT05406362VAD044Phase 1Hereditary Hemorrhagic Telangiectasia (HHT)CardiovascularJan 2027
NCT07743671EngasertibPhase 3Hereditary Hemorrhagic TelangiectasiaCardiovascularJun 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

RHEACELL GmbH & Co. KG Addpharma Cardurion Pharmaceuticals Research Institute of Geroprotective Technologies Aplagon Oy

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.